Overview

Preference Study With Elderly Patients Recurrent Ovarian Cancer

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of therapy for the patient)
Phase:
Phase 3
Details
Lead Sponsor:
North Eastern German Society of Gynaecological Oncology
North Eastern Germany Society of Gynaecologic Oncology
Treatments:
Busulfan
Treosulfan